Geode Capital Management’s BioNexus Gene Lab BGLC Stock Holding History

Geode Capital Management’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,368	Closed	-$5.6K	–	4454
2025 Q1	$5.6K	Hold	2,368	–	–	﹤0.01%	4452
2024 Q4	$6.61K	Hold	2,368	–	–	﹤0.01%	4454
2024 Q3	$10.5K	Hold	2,368	–	–	﹤0.01%	4469
2024 Q2	$11.3K	Hold	2,368	–	–	﹤0.01%	4534
2024 Q1	$16.7K	Hold	2,368	–	–	﹤0.01%	4503
2023 Q4	$12.8K	Hold	2,368	–	–	﹤0.01%	4569
2023 Q3	$19.9K	Buy	+2,368	New	+$38.6K	﹤0.01%	4627

Other funds holding BGLC

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management's BGLC Position: Q2 2025 in Review

Geode Capital Management sold out of BioNexus Gene Lab (BGLC) in Q2 2025, closing a stake of 2,368 shares — an estimated $5.6K sold.

Geode Capital Management first reported a position in BGLC in Q3 2023 and held it in 7 quarters. The position peaked at $19.9K in Q3 2023. 1 fund tracked by Wall St. Rank holds BGLC as of Q2 2025.

Geode Capital Management reported no remaining BioNexus Gene Lab position as of Q2 2025 after selling out during the quarter.
Geode Capital Management sold 2,368 BioNexus Gene Lab shares in Q2 2025, an estimated $5.6K.
Geode Capital Management first reported a position in BioNexus Gene Lab in Q3 2023 and held it in 7 quarters.
Geode Capital Management's BioNexus Gene Lab position peaked at $19.9K in Q3 2023.
1 fund tracked by Wall St. Rank held BioNexus Gene Lab as of Q2 2025.

Based on Geode Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.